Edition:
United Kingdom

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

12.99EUR
18 May 2018
Change (% chg)

€0.18 (+1.41%)
Prev Close
€12.81
Open
€12.80
Day's High
€13.02
Day's Low
€12.71
Volume
21,344
Avg. Vol
61,402
52-wk High
€22.50
52-wk Low
€11.25

Chart for

About

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €301.54
Shares Outstanding(Mil.): 17.56
Dividend: --
Yield (%): --

Financials

  NANOB.PA Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.51 -- --
ROI: -72.64 1.57 14.38
ROE: -81.91 2.43 16.07

BRIEF-Nanobiotix Did Not Generate Any Revenue In Q1

* ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED

16 May 2018

BRIEF-Nanobiotix Partners With Weill Cornell Medicine

* PARTNERSHIP ON PRE-CLINICAL STUDIES TO EVALUATE NBTXR3 IMPACT ON CGAS-STING PATHWAY IN MAMMARY CANCERS

03 May 2018

BRIEF-Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros

* TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016

30 Mar 2018

BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3

* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING

22 Jan 2018

BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers

* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS

11 Jan 2018

BRIEF-Nanobiotix: FDA Approves First Immuno-Oncology Trial

* NANOBIOTIX : FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL

26 Dec 2017

Earnings vs. Estimates